Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects.
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The metabolic fate of very low density lipoprotein can be examined by following the transit of its apolipoprotein B moiety through the delipidation cascade, which leads to low density lipoprotein. In this study we have used cumulative flotation ultracentrifugation to follow the metabolism of various lipoprotein subclasses that participate in this process in normal, hypertriglyceridemic (Type IV), and dysbetalipoproteinemic (Type III) subjects. Large triglyceride-rich very low density lipoproteins of Svedberg units of flotation (Sf) 100-400 were converted virtually quantitatively in normal subjects to smaller Sf 12-100 remnant particles. Only a minor fraction appeared thereafter in low density lipoproteins (Sf 0-12), most being removed directly from the plasma. Type IV hyperlipoproteinemic individuals converted the larger Sf 100-400 very low density lipoproteins to intermediate particles at approximately 50% of the control rate but thereafter their metabolism was normal (fractional clearance of Sf 12-100 particles in controls, 1.29 +/- 0.23 pools/d; in Type IV hypertriglyceridemics, 1.38 +/- 0.23 pools/d; n = 4 in each case). Since the apolipoprotein B in large triglyceride-rich particles did not contribute significantly to the mass of the low density lipoprotein apoprotein pool, the latter must come largely from another source. This was examined by following the metabolic fate of small very low density lipoproteins of Sf 20-60 or of the total lipoprotein spectrum of d less than 1.006 kg/liter (approximate Sf 20-400). The small particles were rapidly and substantially converted to low density lipoproteins, suggesting that the major precursor of the latter was to be found in this density range. Whereas only 10% of apolipoprotein B in Sf 100-400 lipoproteins reached the low density lipoprotein flotation range, greater than 40% of Sf 20-100 B protein eventually appeared in Sf 0-12 particles; and when very low density lipoprotein of d less than 1.006 kg/liter is used as a tracer of apolipoprotein B metabolism it is primarily this population of small very low density lipoprotein particles in the Sf 12-100 flotation range that is labeled. A detailed examination was made of apolipoprotein B metabolism in three dysbetalipoproteinemic subjects. The plasma clearance curves of their Sf 100-400 lipoproteins were distinctly biphasic. The quickly decaying component converted rapidly into remnants of Sf 20-60 at a near normal rate (0.56 vs. 0.62 pools/d in normal subjects). Its subsequent processing, however, was retarded. The more slowly catabolized fraction, comprising 30% of the total apolipoprotein B radioactivity, had no counterpart in normal or Type IV hyperlipoproteinemic individuals. These data, taken together, suggest that the very low density lipoprotein consists of a complex mixture of particles with different origins and fates. Within the Sf 20-100 flotation range there are at least two subcomponents. One represents remnants of larger triglyceride-rich particles which are catabolized slowly and feeds little apolipoprotein B into low density lipoprotein. The other is apparently secreted directly into this flotation interval and transfers significant amounts of B protein rapidly into Sf 0-12 lipoproteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,760
Bilheimer, D. W., Eisenberg, S., & Levy, R. I. (1972) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(72)90034-3 · Cited by 1,818
Identification of multiple subclasses of plasma low density lipoproteins in normal humans.
Krauss, R. M., & Burke, D. J. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38178-5 · Cited by 992
Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons.
Kane, J. P., Hardman, D. A., & Paulus, H. E. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.5.2465 · Cited by 584
Krauss, R. M., Levy, R. I., & Fredrickson, D. S. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107855 · Cited by 437
Apoprotein composition of very low density lipoproteins of human serum.
Kane, J. P., Sata, T., Hamilton, R. L., & Havel, R. J. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108245 · Cited by 375
Sata, T., Havel, R. J., & Jones, A. L. (1972) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39346-9 · Cited by 359
Heterogeneity of serum low density lipoproteins in normal human subjects.
Shen, M. M., Krauss, R. M., Lindgren, F. T., & Forte, T. M. (1981) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35367-0 · Cited by 354
Mjos, O. D., Faergeman, O., Hamilton, R. L., & Havel, R. J. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108130 · Cited by 322
Sigurdsson, G., Nicoll, A., & Lewis, B. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108229 · Cited by 308
Cited by
Walsh, B. W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., & Sacks, F. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251702 · Cited by 1,152
Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review
Harris, W. S. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38310-3 · Cited by 1,127
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
“(25, 26) since their delipidation generally ceases in the VLDL or IDL density range with the formation of rem-”
BackgroundLipoprotein metabolism in diabetes mellitus.
Howard, B. V. (1987) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38659-4 · Cited by 636
Mori, T. A., Burke, V., Puddey, I. B., Watts, G. F., O’Neal, D. N., Best, J. D., & Beilin, L. J. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.5.1085 · Cited by 588
Postprandial lipoproteins and progression of coronary atherosclerosis
Karpe, F., Steiner, G., Uffelman, K., Olivecrona, T., & Hamsten, A. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90085-x · Cited by 483
[1] Introduction to the plasma lipoproteins
Gotto, A. M., Pownall, H. J., & Havel, R. J. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)28061-1 · Cited by 421
Self-citationLipoprotein Heterogeneity and Apolipoprotein B Metabolism
Packard, C. J., & Shepherd, J. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.12.3542 · Cited by 402
Self-citationAbnormal in vivo metabolism of apolipoprotein E4 in humans.
Gregg, R. E., Zech, L. A., Schaefer, E. J., Stark, D., Wilson, D., & Brewer, H. B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112645 · Cited by 345
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Self-citationZilversmit, D. B. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.1.153 · Cited by 262
Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans
Reyes-Soffer, G., Pavlyha, M., Ngai, C., Thomas, T., Holleran, S., Ramakrishnan, R., Karmally, W., Nandakumar, R., Fontanez, N., Obunike, J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025253 · Cited by 240
Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans
Rambjør, G. S., W»len, A. I., Windsor, S. L., & Harris, W. S. (1996) · Lipids · doi:10.1007/bf02637050 · Cited by 147
Demant, T., Bedford, D., Packard, C. J., & Shepherd, J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115459 · Cited by 145
Self-citationEffects of simvastatin on apoB metabolism and LDL subfraction distribution
Gaw, A., Packard, C. J., Murray, E. F., Lindsay, G. M., Griffin, B. A., Caslake, M. J., Vallance, B. D., Lorimer, A. R., & Shepherd, J. (1993) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.13.2.170 · Cited by 104
“Lipoprotein Isolation and Labeling The methods for preparation of the tracer VLDL subfractions VLDL, (Sf 60-400) and VLDL2 (Sf 20-60) have been described in detail elsewhere.(23) Briefly, 250 ml fasting plasma was collected by plasmapheresis and from this, total VLDL (d< 1.”
MethodSelf-citationThomas, T., Zhou, H., Karmally, W., Ramakrishnan, R., Holleran, S., Liu, Y., Jumes, P., Wagner, J. A., Hubbard, B., Previs, S. F., et al. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309549 · Cited by 96
Rodríguez‐Villar, C., Pérez‐Heras, A., Mercadé, I., Casals, E., & Ros, E. (2004) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01086.x · Cited by 84
Stalenhoef, A. F., Malloy, M. J., Kane, J. P., & Havel, R. J. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112632 · Cited by 70
Björnson, E., Packard, C. J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Lundbom, J., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13017 · Cited by 46
Self-citationMarcoux, C., Hopkins, P. N., Wang, T., Leary, E. T., Nakajima, K., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33455-6 · Cited by 43
Metadata
- Authors
- Packard, C. J., Munro, A., Lorimer, A. R., Gotto, A. M., & Shepherd, J.
- Venue
- Journal of Clinical Investigation
- Published
- 1984-12-01
- Volume
- 74
- Issue
- 6
- Pages
- 2178-2192
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1977359700
- Cited by
- 298
- References
- 25
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.